1. Home
  2. ENTX vs MCHX Comparison

ENTX vs MCHX Comparison

Compare ENTX & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • MCHX
  • Stock Information
  • Founded
  • ENTX 2010
  • MCHX 2003
  • Country
  • ENTX Israel
  • MCHX United States
  • Employees
  • ENTX N/A
  • MCHX N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • MCHX Business Services
  • Sector
  • ENTX Health Care
  • MCHX Consumer Discretionary
  • Exchange
  • ENTX Nasdaq
  • MCHX Nasdaq
  • Market Cap
  • ENTX 67.2M
  • MCHX 79.9M
  • IPO Year
  • ENTX 2018
  • MCHX 2004
  • Fundamental
  • Price
  • ENTX $1.73
  • MCHX $1.70
  • Analyst Decision
  • ENTX Strong Buy
  • MCHX
  • Analyst Count
  • ENTX 1
  • MCHX 0
  • Target Price
  • ENTX $10.00
  • MCHX N/A
  • AVG Volume (30 Days)
  • ENTX 127.7K
  • MCHX 33.5K
  • Earning Date
  • ENTX 11-08-2024
  • MCHX 10-31-2024
  • Dividend Yield
  • ENTX N/A
  • MCHX N/A
  • EPS Growth
  • ENTX N/A
  • MCHX N/A
  • EPS
  • ENTX N/A
  • MCHX N/A
  • Revenue
  • ENTX $99,000.00
  • MCHX $48,594,000.00
  • Revenue This Year
  • ENTX N/A
  • MCHX N/A
  • Revenue Next Year
  • ENTX N/A
  • MCHX $4.20
  • P/E Ratio
  • ENTX N/A
  • MCHX N/A
  • Revenue Growth
  • ENTX 607.14
  • MCHX N/A
  • 52 Week Low
  • ENTX $0.52
  • MCHX $1.11
  • 52 Week High
  • ENTX $3.35
  • MCHX $2.15
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 44.32
  • MCHX 45.01
  • Support Level
  • ENTX $1.64
  • MCHX $1.67
  • Resistance Level
  • ENTX $1.80
  • MCHX $1.90
  • Average True Range (ATR)
  • ENTX 0.09
  • MCHX 0.13
  • MACD
  • ENTX -0.01
  • MCHX -0.00
  • Stochastic Oscillator
  • ENTX 30.00
  • MCHX 33.33

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About MCHX Marchex Inc. Class B

Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.

Share on Social Networks: